The effect of growth hormone adjuvant therapy on assisted reproductive technologies outcomes in patients with diminished ovarian reserve or poor ovarian response
The effect of growth hormone adjuvant therapy on assisted reproductive technologies outcomes in patients with diminished ovarian reserve or poor ovarian response
复制标题
DOI：
10.1016/j.jogoh.2020.101982
复制
发表时间：
2021-02-01
影响因子：
1.9
通讯作者：
Sertel, Emre
中科院分区：
文献类型：
--
作者：
Dogan, Sare;Cicek, Ozge Senem Yucel;Sertel, Emre
卵巢储备功能减退患者在控制性促排卵（COS）方案中对外源性促性腺激素的低反应性是生殖内分泌学的重要问题之一。在卵巢储备功能减退（DOR）或卵巢反应不良（POR）患者中，已开发出各种治疗方案。最近，在这些患者的治疗方案中添加生长激素（GH）已被提上议程。在这项研究中，我们的目的是探讨GH辅助治疗对DOR或POR患者卵胞浆内单精子注射（ICSI）周期结果的影响。这项回顾性队列研究在诊断为DOR或POR并接受ICSI的患者中进行。根据是否使用GH将患者分组。在本研究中，观察到接受GH的组中的持续妊娠率和活产率显著高于对照组。此外，在接受GH的组中胚胎质量显著增加。因此，在DOR和POR患者的COS方案中添加GH可能会提高继续妊娠率、活产率和胚胎质量。(C)2020 Elsevier Masson SAS。All rights reserved.
Low response of patients with diminished ovarian reserve to exogenous gonadotropins in controlled ovarian stimulation (COS) protocols is one of the important problems of reproductive endocrinology. Various treatment protocols have been developed in patients with diminished ovarian reserve (DOR) or poor ovarian response (POR). Recently, the addition of growth hormone (GH) to treatment protocols has been brought to the agenda in these patients. In this study, we aimed to investigate the effect of GH adjuvant treatment on intracytoplasmic sperm injection (ICSI) cycle results in patients with DOR or POR. This retrospective cohort study was carried out with patients who diagnosed as DOR or POR and underwent ICSI. The patients were divided into the groups according to whether GH was used. In this study, ongoing pregnancy rates and live birth rates were observed to be significantly higher in the group receiving GH compared to the control group. In addition, there was a significant increase in embryo quality in the group receiving GH. As a result, the addition of GH to COS protocols in DOR and POR patients may increase the ongoing pregnancy rate, live birth rate, embryo quality. (C) 2020 Elsevier Masson SAS. All rights reserved.